Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Monsanto Company (MON): These Chemical Giants Deserve a Stinging Rebuke

Naturally the chemical manufacturers say the concerns are overblown, with sufficient study in the field proving the chemicals’ safety. Yet in a bid to contain what damage might be done to their investment, the chemical makers have also begun studying bee health in earnest themselves. Bayer has opened “bee care centers,” Syngenta AG (ADR) (NYSE:SYT) is funding research into CCD, and Monsanto Company (NYSE:MON) even purchased the leading bee research firm Beelogics.

While such investments would seem to show concern for the health of bees, it’s also pretty much a case of the fox guarding the henhouse. Beelogics was one of the leading researchers into CCD, and now one of the possible culprits owns it. I think Monsanto Company (NYSE:MON) cares not so much for the research conclusions per se but rather its work in genetically modifying the bees themselves. It is seeking patent protection for its RNAi-based — meaning the bees’ genetic code — treatment, which raises the obvious threat of what happens to the beekeepers whose bees get crossbred with Monsanto Company (NYSE:MON)’s? If history with its seeds is any guide, it will go after them legally for violating their patents.

Ultimately, Monsanto Company (NYSE:MON) and the other biotechs need more than just a stinging rebuke from investors for their role in causing the collapse of bee colonies and the threat it poses to our food supply.

The article These Chemical Giants Deserve a Stinging Rebuke originally appeared on and is written by Rich Duprey.

Fool contributor Rich Duprey and The Motley Fool have no position in any stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.